Exosome Technologies Market Value to Reach USD 343.5 Mn by 2031, rising at a CAGR of 24.8%: TMR Study

Surge in usage of targeted drug delivery systems to treat a range of diseases, especially chronic diseases, is likely to propel the exosome technologies market. Rise in demand for mesenchymal stem cells (MSCs)-derived exosomes in therapeutic applications is expected to offer significant business opportunities to companies.

Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global exosome technologies market was valued at USD 47.3 Mn in 2022 and is projected to exceed USD 343.5 Mn by 2031.

Companies in the global exosome technologies market are developing exosome-based products to meet demand for non-invasive diagnosis and treatment of a range of diseases, including cardiovascular diseases, neurodegenerative diseases, and cancer. Rise in applications of targeted delivery system of exosomes in disease treatment is anticipated to bolster the market.

Download a Sample for Highlights on Market Drivers and Challenges Affecting the Exosome Technologies: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=65840

Rise in awareness about benefits of exosome-based biomarkers for efficient diagnosis of cancer is anticipated to fuel global exosome technologies market development. However, lack of standards and established guidelines on exosome extraction and production has hampered market expansion. An example is the lack of protocols for production, isolation, and storage of MSC-derived exosomes. Nevertheless, continuous R&D activities in their separation and purification methods are likely to broaden market outlook in the near future.

Increase in awareness about prognostic, diagnostic, and therapeutic aspects of exosome across the healthcare industry is likely to bolster the exosome technologies industry. Recent market trends indicate exosome technologies are rapidly emerging as early-stage diagnostic marker for complex ailments, especially cancer. Rapid increase in adoption of exosomes as novel biomarker for diagnosis and prognosis of chronic diseases, particularly those that have high incidence rate, is likely to accelerate market development.

Key Findings of Study

  • Rise in Usage of Loaded Cargo Exosomes in Disease Treatment: Based on exosome type, the loaded cargos segment is anticipated to account for the leading market share from 2023 to 2031. Rise in usage of exosomes as drug delivery systems for a range of biological components, such as small molecules, genetic materials, and cytokines, is expected to bolster the segment. Surge in demand for exosome-targeted drug delivery system can be ascribed to better biocompatibility and lower immunogenicity than most nano-delivery systems.
  • Surge in Demand for Exosome-based Biomarkers for Diagnosis of Diseases: Surge in usage of exosome-based biomarkers for efficient diagnosis of cancer and other chronic diseases is likely to offer lucrative opportunities to companies in the market. Rise in need for novel diagnostic biomarkers for cancer is expected to bolster the market. Based on cell sources, the MSCs (mesenchymal stem cells) segment accounted for leading market share in 2022. Surge in demand for MSC-derived exosomes for the treatment of kidney, liver, heart, immune, and neurological diseases is likely to propel the MSCs segment. Furthermore, considerable research in exploring therapeutic role of mesenchymal stem cell-derived exosomes in regenerative medicine for range of diseases is expected to fuel the segment in the near future.

Get Customized Solution to Meet Your Research Requirements: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=65840

Key Drivers

  • Rapid increase in global burden of chronic diseases, especially cancer, is a key driver of the exosome technologies market. Surge in cancer morbidity and mortality is anticipated to encourage industry investments in R&D activities in non-invasive diagnostic methods. Exosome technologies are being extensively researched for early diagnosis of cancer. An example is usage of exosomes as a liquid biopsy.
  • Rise in government investment in projects on the development of exosomes as cell-based pharmaceutical to treat a range of diseases is likely to propel the exosome technologies industry. An instance is initiative by the Government of Australia to support VivaZome Therapeutics Pty Ltd. for a three-year project for promoting an exosome manufacturing facility.

Regional Growth Dynamics

North America is anticipated to account for the leading market share in the next few years. The U.S. is a lucrative market in the region. Rise in demand for novel therapies and diagnostics for cancer is likely to drive rapid commercialization of exosome-based products. Surge in government initiatives to support the manufacture of these products in the region is anticipated to augment market value (North America). Global biotechnology firms in the region are partnering with government and private universities to scale-up manufacturing of therapeutic extracellular vesicles from MSCs and other stem cells.

Asia Pacific is projected to record significant growth from 2023 to 2031. Rise in investment in development of effective therapeutics and diagnostics for chronic diseases, especially in emerging economies is likely to bolster market development in Asia Pacific. Increase in focus on regenerative medicine and surge in research in targeted therapy applications are likely to fuel market growth in Asia Pacific.

Competition Landscape

Product launches, mergers & acquisitions, and divestiture are key competitive strategies in the global exosome technologies market.

Prominent companies in the market are AEGLE Therapeutics, Thermo Fisher Scientific, Aruna Bio Inc., OmniSpirant Ltd., Bio-Techne Corporation, Creative Biolabs, Novadip Biosciences S.A., Carmine Therapeutics, Inc., and Danaher Corporation (Beckman Coulter Inc.).

For In-Depth Competitive Analysis, Buy this Report Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=65840&ltype=S

Exosome Technologies Market Segmentation

Exosome Type

  • Loaded Cargos
    • Peptide
    • siRNA
    • mRNA
    • miRNA
    • Protein
    • Chemical
    • Others
  • Non-cargo
    • HEK293 Cells
    • MSCs
    • Platelets
    • Erythrocytes
    • Natural Killer Cells
    • Others


  • Therapeutics
    • Oncology
    • Neurodegenerative Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Cosmetics
    • Others
  • Diagnostics


  • Health Care Providers
  • Pharmaceutical & Biotechnology Companies
  • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Nikhil Sawlani
Transparency Market Research Inc.
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com